$FEMY Balance Sheet | Understand Stock

$FEMY

$1.37 -$0.04 (2.84%) Close

$FEMY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash and cash equivalents
Accounts receivable, net
Inventory
Prepaid and other current assets
Total current assets
Property and equipment, at cost:
Leasehold improvements
Office equipment
Furniture and fixtures
Machinery and equipment
Construction in progress
Property and equipment, gross
Less accumulated depreciation
Net property and equipment
Long-term assets:
Lease right-of-use assets, net
Intangible assets, net of accumulated amortization
Other long-term assets
Total long-term assets
Total assets
Current liabilities:
Accounts payable
Accrued expenses
Note payable
Convertible notes payable, net (including related parties)
Clinical holdback – current portion
Lease liabilities - current portion
Other - current
Operating lease liabilities – current portion
Total current liabilities

Long-term liabilities:
Clinical holdback – long-term portion
Note payable - long-term portion
Lease liabilities - long-term portion
Other - long-term
Convertible notes payable, net
Conversion option liability
Warrants liabilities
Operating lease liabilities – long-term portion
Total long-term liabilities
Total liabilities

Preferred stock
Stockholders' equity:
Common stock, $0.001 par, 200,000,000 authorized, 3,029,829 shares issued and 3,023,967 outstanding as of June 30, 2026; and 2,986,116 shares issued and 2,980,254 outstanding as of December 31, 2025
Treasury stock, 117,223 shares
Preferred stock, Series A, $.001 par, none authorized, issued and outstanding as of December 31, 2021; 17,310,609 shares authorized, and 17,210,609 shares issued and outstanding as of December 31, 2020
Treasury stock, 5,862 common shares
Warrants
Additional paid-in capital
Accumulated other comprehensive loss, net of tax
Accumulated deficit
Total stockholders’ equity

Total liabilities and stockholders’ equity

Comments